CN103494810A - Pharmaceutical composition for treating Internet addiction - Google Patents
Pharmaceutical composition for treating Internet addiction Download PDFInfo
- Publication number
- CN103494810A CN103494810A CN201310440401.4A CN201310440401A CN103494810A CN 103494810 A CN103494810 A CN 103494810A CN 201310440401 A CN201310440401 A CN 201310440401A CN 103494810 A CN103494810 A CN 103494810A
- Authority
- CN
- China
- Prior art keywords
- addiction
- pharmaceutical composition
- compositions
- internet addiction
- clonidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating Internet addiction. The active ingredients of the pharmaceutical composition include sodium succinate and clonidine at a weight ratio of (500-100):(0.1-5). The composition disclosed by the invention is used for treating Internet addiction and is safe and effective with a remarkable clinical effect and shows a good curative effect on an animal ignition model and 30 Internet addiction volunteers; moreover, the result of an acute toxicity test on the composition indicates that the LD50 is 5.84g.kg<-1>, the 90% confidence limit is 4.56-7.73g.kg<-1> and the toxicity is low.
Description
Technical field
The present invention relates to the pharmaceutical composition technical field, especially a kind of pharmaceutical composition for the treatment of network addiction.
Background technology
At present the whole world in the netizen, approximately has 1,140 ten thousand people to suffer from the network mental maladjustment of certain form more than 200,000,000, accounts for 6% of netizen's number, and research discovering network addiction occurs that various actions are abnormal, mental maladjustment and sympathetic nerve function imbalance.Once stop online, just there will be acute withdrawal syndrome, even take autotomy or suicide means, harm individual and social safety.Therefore, it is anxious to be resolved that the network addiction problem has become a very serious social problem.
The Therapeutic Method of network addiction mainly contains psychological counseling at present, intervenes uncertain therapeutic efficacy and cuts, and lacks effective Therapeutic Method.Extensively think and as dopamine and norepinephrine etc., in the formation of addiction, play an important role the interior catecholamines in boys of brain, norepinephrine can regulate and control the release of γ-tyrosine (GABA).There are some researches show that GABA is relevant with addiction, GABA participates in the reward system of brain, the release of GABA serotonergic neuron regulation and control dopamine.Network addiction, as a kind of form of addiction, has the neurobiology basis similar to other forms of addiction.
Addiction is a kind of pathologic learning and memory process, and the long time-histories that synapse is transmitted strengthens (LTP) and long time-histories inhibition (LTD) is the electrophysiological index of learning and memory, is its functional attributes of synaptic plasticity, in the formation of addiction, plays a significant role.Light (Kindling) relevant with the acquistion neuropsychiatric disease, can change function and the plasticity of nerve synapse, proved relevantly with addictive disorders, thereby light the mechanism that relates to network addiction.
Still network addiction is not had to definite curative effect and low, the cheap patent medicine of toxic and side effects at present.Therefore, explore a kind of high-efficiency low-toxicity, cheap, the medicine that is easy to promote becomes problem demanding prompt solution.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, propose a kind of pharmaceutical composition for the treatment of network addiction, both kept the anti-addiction effect that medicine is good, reduce again toxic and side effects.
In order to realize the foregoing invention purpose, the invention provides following technical scheme: a kind of pharmaceutical composition for the treatment of network addiction, its effective ingredient is comprised of sodium succinate and the clonidine of weight ratio 500～100 ︰ 0.1～5.
Preferably, the weight ratio of sodium succinate and clonidine is 1000 ︰ 1.
Succinic acid (Succinate) is the neural lead compound of natural activity, also a kind of endogenous neuromodulator (Yue Wang, Acta Pharmaceutica Sinica, 2000), research finds that its calmness, convulsion and antiepileptic action and the effect of Chinese medicine succinum match, and its chemical structure effect is similar to inhibitory aminoacid neurotransmitter GABA in brain.This natural lead compound chemical constitution is clear and definite, avirulence, and can improve cognitive function, there is good using value and DEVELOPMENT PROSPECT.
Existing research shows that in brain, monoamines participates in the addiction pathogenesis, and in brain, norepinephrine increases, and suppresses addiction.Clonidine (Clonidine) is α
2specific agonist, it is by postsynaptic epinephrine α
2receptor suppresses kindled seizure (Zhang Fang, Chinese drug dependence magazine, 2005), and research shows that it has obvious anti-addiction effect (Qingdao City science and technology office problem, 2005).But, due to its toxic and side effects, as Blood pressure drop, decreased heart rate etc., limited its clinical practice.
Succinic acid and clonidine combine in proportion and are used for the treatment of network addiction, and safe and effective clinical effectiveness is remarkable, at animal kindling model and network addiction volunteer 30 examples, all obtain good efficacy, and the demonstration of compositions the acute toxicity tests, LD
50for 5.84g.kg
-1, the 95% credible 4.56-7.73g.kg that is limited to
-1, toxicity is lower.
The specific embodiment
Below in conjunction with specific embodiment, describe the present invention, the description of this part is only exemplary and explanatory, should any restriction not arranged to protection scope of the present invention.
Embodiment 1
A kind of pharmaceutical composition for the treatment of network addiction, for by the quality tablet that following composition forms respectively:
Succinic acid 100mg, clonidine 0.1mg, lactose 249.9mg, microcrystalline Cellulose 110mg, carboxylic formaldehyde cellulose calcium 10mg, anhydrous silicic acid 10mg, carboxyl propionyl cellulose 15mg, magnesium stearate 5mg;
By succinic acid, clonidine, lactose, microcrystalline Cellulose, carboxylic formaldehyde cellulose calcium, anhydrous silicic acid, evenly mix then and dissolve carboxyl propionyl cellulose with isopropyl alcohol, mix above composition, by wet granulation, drying, after granulate, with magnesium stearate, mix, tabletting, make every pure heavy be the tablet of 500mg.
Embodiment 2
A kind of pharmaceutical composition for the treatment of network addiction, for by the quality capsule that following composition forms respectively:
Succinic acid 500mg, clonidine 0.1mg, medical starch 394.9mg, magnesium stearate 5mg;
By each self-weighing mix homogeneously of above composition, filled capsules, make each pure heavy be the capsule of 500mg.
Embodiment 3
A kind of pharmaceutical composition for the treatment of network addiction, for by the quality aqueous solution that following composition forms respectively: succinic acid 480mg, clonidine 4.6mg, be dissolved in 1000ml water, mix.
The experimentation of test example 1 combination treatment addiction
Animal experiment study:
The Wistar rat, body weight 180 ± 10g; Kunming mouse, body weight 18 ± 2g, male and female have concurrently, and effluent south provincial institute for drug control animal center provides.Animal conforms one week in the preposition laboratory of experiment, ad lib, drinking-water; Fasting 10h before mouse experiment.Control 23 ± 20 ℃ of room temperatures, the illumination of 12/12h day-night cycle; Experiment all starts at 9:00am, and quiet in holding chamber.
The inhibitory action of compositions to PTZ chemistry kindled seizure
Compositions 100～200mg.kg
-1ip all reduces average classification and is dose-effect relationship (P ﹤ 0.05, P ﹤ 0.01), and the percentage rate of 6 grades of outbreaks obviously reduces (P ﹤ 0.05, P ﹤ 0.01) (table 1).
The impact of table 1 compositions on PTZ chemistry kindled seizure
With comparison before administration
ap ﹤ 0.05,
bp ﹤ 0.01
The impact of compositions on the electricity irritation kindled seizure
Compositions has and affects and be dose-effect relationship the ADT of electricity irritation kindled rats.In the compositions that gives various dose at every turn first four days, measure its ADT to the animal injecting normal saline and when recording EEG, electric discharge and diving, the indexs such as ADD and intensity of attack.30min after the compositions pretreatment, measure ADT again.Found that: mixture 50～200mg.kg
-1the ip ADT that all can significantly raise, and be dose-effect relationship, at 200mg.kg
-1shi Zuoyong is (P ﹤ 0.01) the most obviously.
All show the V order reaction with the ADT stimulating animal under collating condition.Compositions 50～200mg.kg
-1with original ADT stimulation, generally can not bring out ADD or of short duration epilepsy electric discharge only occur after processing, now rat without or only have minor response (generally not reaching the V order reaction).Record Racine ' the s classification of every rat, found that: 50～200mg.kg
-1the compositions of ip can reduce average intensity of attack (table 2).
The impact of table 2 compositions on corpus amygdaloideum electricity irritation kindled seizure
With comparison before administration
ap ﹤ 0.05,
bp ﹤ 0.01
The mechanism of action experimentation of test example 2 combination treatment addiction
Compositions is to GABA
athe receptor antagonist picrotoxin is brought out the effect of mice convulsion
Compositions 50～200mg.kg
-1ip, but significant prolongation GABA
aantagonist picrotoxin convulsions mice incubation period, and be dose-effect relationship in this scope.With the normal saline group, compare, each is organized and all on average extends (table 3) incubation period.
Table 3 compositions is to GABA
athe receptor antagonist picrotoxin is brought out the effect of mice convulsion
With the normal saline matched group, compare
ap ﹤ 0.05,
bp ﹤ 0.01
The clinical experimental study of test example 3 combination treatment network addictions
Object of study is network addiction volunteer 60 people, male 43 examples wherein, female's 17 examples.12～38 years old age, average (22 ± 8) year.Be divided at random two groups: matched group 30 examples, compositions group 30 examples.Between two groups on age, the course of disease no significant difference.
Test method
Matched group is taken vitamin e1 0mg/ time, q8h; The compositions group is taken compositions 1000mg/ time, q8h.After February, utilize YoungShi Internet Addiction Test method respectively each group to be carried out to repetition measurement.Efficacy determination: with clinical global impression scale (CGI) evaluation, and follow up a case by regular visits to half a year.
Each organizes curative effect relatively: effectively, 7 examples are invalid for compositions group 23 examples, with the more equal difference of matched group remarkable (P ﹤ 0.01).YoungShi scoring before and after each group treatment: compositions group and matched group significant difference (P ﹤ 0.01).(table 4)
Before and after each group treatment of table 4, compare
With matched group, compare
ap ﹤ 0.01
Test example 4: compositions acute toxicity test
The anxious poison of composition tablet mouse stomach is measured: mice is divided into 5 groups, and 10 every group, observe 7d after gastric infusion, death condition respectively organized in record, and calculating its LD50 value with SPSS13.0 is 5.84g.kg
-1, the 95% credible 4.56-7.73g.kg that is limited to
-1, toxicity is lower.
The acute toxicity test of table 5 compositions
Result of the test shows: present composition acute toxicity, LD
50for 5.84g.kg
-1, the 95% credible 4.56-7.73g.kg that is limited to
-1, toxicity is lower.
Claims (2)
1. a pharmaceutical composition for the treatment of network addiction, its effective ingredient is comprised of sodium succinate and the clonidine of weight ratio 500～100 ︰ 0.1～5.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that: the weight ratio of sodium succinate and clonidine is 1000 ︰ 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310440401.4A CN103494810A (en) | 2013-09-25 | 2013-09-25 | Pharmaceutical composition for treating Internet addiction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310440401.4A CN103494810A (en) | 2013-09-25 | 2013-09-25 | Pharmaceutical composition for treating Internet addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103494810A true CN103494810A (en) | 2014-01-08 |
Family
ID=49860136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310440401.4A Pending CN103494810A (en) | 2013-09-25 | 2013-09-25 | Pharmaceutical composition for treating Internet addiction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494810A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015782A2 (en) * | 2001-07-25 | 2003-02-27 | Kox Wolfgang J | Receptor-adapted nicotine withdrawal by anti-cholinergic and anti-noradrenergic blockage |
| CN101829076A (en) * | 2009-03-10 | 2010-09-15 | 陈建操 | Medicament for treating Internet addition disorder or Internet addition disorder syndrome |
| WO2011020949A1 (en) * | 2009-08-18 | 2011-02-24 | M-Real Oyj | Method of producing sodium hydroxide from an effluent of fiber pulp production |
-
2013
- 2013-09-25 CN CN201310440401.4A patent/CN103494810A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015782A2 (en) * | 2001-07-25 | 2003-02-27 | Kox Wolfgang J | Receptor-adapted nicotine withdrawal by anti-cholinergic and anti-noradrenergic blockage |
| CN101829076A (en) * | 2009-03-10 | 2010-09-15 | 陈建操 | Medicament for treating Internet addition disorder or Internet addition disorder syndrome |
| WO2011020949A1 (en) * | 2009-08-18 | 2011-02-24 | M-Real Oyj | Method of producing sodium hydroxide from an effluent of fiber pulp production |
Non-Patent Citations (1)
| Title |
|---|
| 李晓玲: "网络成瘾的动物模型制备及发病机制研究", 《医学创新研究》, vol. 5, no. 12, 30 April 2008 (2008-04-30), pages 21 - 23 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Activation of serotonin 5-HT2C receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice | |
| Beppe et al. | Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson’s disease | |
| Pathan et al. | Anxiolytic and analgesic effect of seeds of Coriandrum sativum Linn | |
| Mo et al. | L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease | |
| Alzubier et al. | Investigation of anti-inflammatory, antipyretic and analgesic effect of Yemeni Sidr honey | |
| Szczytkowski-Thomson et al. | Morphine prevents the development of stress-enhanced fear learning | |
| Paixão et al. | Hyptis pectinata: redox protection and orofacial antinociception | |
| Salat et al. | Analgesic, anticonvulsant and antioxidant activities of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one dihydrochloride in mice | |
| Dekundy et al. | Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L-DOPA-induced dyskinesia | |
| Zhao et al. | (6aR)-11-Amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease | |
| WO2014176942A1 (en) | Use of instant asparagus powder in food, medicine and health food | |
| Li et al. | A safer hypoglycemic agent for type 2 diabetes—Berberine organic acid salt | |
| Cedillo et al. | Effects of co-administration of the GABAB receptor agonist baclofen and a positive allosteric modulator of the GABAB receptor, CGP7930, on the development and expression of amphetamine-induced locomotor sensitization in rats | |
| US9023788B2 (en) | Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
| Jackson et al. | Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets | |
| Mondal et al. | Evaluation of Analgesic, Antipyretic and Anti-Inflammatory Effects of Ethanol Extract from a Fern Species Macrothelypteris Torresiana (Gaudich) Aerial Parts. | |
| EA031559B1 (en) | Opioid receptor modulator dosage formulations | |
| Muccillo-Baisch et al. | Evaluation of the analgesic effect of aqueous extract of Brugmansia suaveolens flower in mice: possible mechanism involved | |
| Mihara et al. | A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs | |
| CN103494810A (en) | Pharmaceutical composition for treating Internet addiction | |
| Kukuia et al. | Antidepressant effects of mallotus oppositifolius in acute murine models | |
| Wang et al. | Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia | |
| Bai et al. | A comparison of the effects of digoxin, ouabain and milrinone on naloxone-precipitated withdrawal syndrome in mice | |
| CN104623671A (en) | Compound medicine composition containing acetylcholinesterase inhibitor and metformin | |
| Moradi et al. | Assessment of Hyoscyamus niger seeds alcoholic extract effects on acute and chronic pain in male NMRI rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140108 |